Multi-omics analysis identifies LANCL2 as a potential biomarker for the diagnosis and prognosis of gastric cancer.

ABSTRACT: Gastric cancer (GC) constitutes a significant global public health burden due to its high morbidity rates and poor prognosis, underscoring the critical need for identifying novel therapeutic targets and elucidating their mechanisms. As a key member of the lanthionine synthetase C-like enzyme family, LANCL2 has shown aberrant expression in multiple malignancies. However, its biological significance in GC remains unclear. To this end, a series of exploration and research were conducted. Through integrated analyses of multi-omics databases and experimental validation, LANCL2 was up-regulated in STAD at both mRNA and protein levels. Moreover, elevated LANCL2 is closely associated with poor prognosis, and the constructed nomogram exhibited reliable predictive performance for 1, 3, and 5-year ov

SUBMITTER: Fang X 

PROVIDER: S-EPMC12104457 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature